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London, United KingdomOBJECTIVES This study was devised to describe the different cardiac magnetic resonance (CMR)
appearances in light chain amyloid (AL) and transthyretin-related amyloidosis (ATTR).
BACKGROUND CMR is increasingly used to investigate patients with suspected amyloidosis. Global
subendocardial late gadolinium enhancement (LGE) has been reported as typical of AL amyloidosis,
whereas different patterns have been noted in ATTR amyloidosis.
METHODS We performed de novo analyses on original DICOM magnetic resonance imaging in 46
patients with cardiac AL amyloidosis and 51 patients with ATTR type who had been referred to a
specialist amyloidosis center between 2007 and 2012 after CMR. Histological examination was performed
in all cases, with immunohistochemistry, to conﬁrm systemic amyloidosis.
RESULTS Patients’ median age was 68  10 years, and 74% were male. Left ventricular mass was
markedly increased in ATTR amyloidosis (228 g [202 to 267 g]) compared with AL type (167 g [137 to
191 g]) (p < 0.001). LGE was detected in all but 1 cardiac amyloidosis patient (AL type) and was substan-
tially more extensive in ATTR compared with AL amyloidosis. Ninety percent of ATTR patients demon-
strated transmural LGE compared with 37% of AL patients (p < 0.001). Right ventricular LGE was
apparent in all ATTR patients but in only 33 AL patients (72%) (p < 0.001). Despite these ﬁndings, survival
was signiﬁcantly better in cardiac ATTR amyloidosis compared with AL type. We derived an LGE scoring
system (Query Amyloid Late Enhancement) that independently differentiated ATTR from AL amyloidosis
and, when incorporated into a logistic regression model with age and wall thickness, detected ATTR type
with 87% sensitivity and 96% speciﬁcity.
CONCLUSIONS Transmural patterns of LGE distinguished ATTR from AL cardiac amyloidosis with
high accuracy in this real-world analysis of CMR. Precise diagnosis of cardiac amyloidosis is crucial given
the role of chemotherapy in AL type and with novel therapies for ATTR type currently in
development. (J Am Coll Cardiol Img 2014;7:133–42) ª 2014 by the American College of Cardiology
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SA B B R E V I A T I O N S
A N D A C R O N YM S
AL = light chain amyloid
ATTR = transthyretin-relate
amyloidosis
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
DPD = 99mTc-3,3-diphos- p
1,2-propanodicarboxylic ac
LGE = late gadolinium
enhancement
LV = left ventricular
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal
pro–B-type natriuretic pep
QALE = Query Amyloid
Late Enhancement
RV = right ventricular
TTR = transthyretin
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134ystemic amyloidosis is a condition character- a specialist referral center for the analysis of systemic
ized by extracellular deposition of pathologic
insoluble ﬁbrillar proteins (1). Cardiac light
chain amyloid (AL) amyloidosis, in which
amyloid ﬁbrils are derived from monoclonal immu-
noglobulin light chains, is associated with poor
prognosis, with a median survival from diagnosis of
<12 months (2,3). The prognosis of transthyretin-
related amyloidosis (ATTR) is typically 3 to 5 years
(4). Transthyretin (TTR) is a plasma protein,See page 166predominantly synthesized in the liver, which acts as
a transporter for thyroxine and retinol-binding pro-
tein (5). Senile systemic amyloidosis due to nonmu-d
hono-
id
tidetant (wild-type) TTR is a sporadic disease
among older people presenting as isolated
cardiomyopathy. Hereditary ATTR am-
yloidosis is an autosomal dominant disease
associated with >100 transthyretin gene
mutations (6). Cardiac involvement is now
known to occur in association with most
hereditary ATTR variants.
There has been a marked increase (143%)
in new cases of ATTR amyloidosis referred
to our center in the past 5 years (4). The
increased detection of ATTR amyloidosis
correlates with increased availability of
cardiac magnetic resonance (CMR) for in-
vestigation of cardiomyopathy. Gadolin-
ium-enhanced CMR visualizes expansion of
the interstitial space and may be used to
demonstrate the accumulation of abundant
amyloid in this site (7). An early CMR study
in cardiac amyloidosis described altered
gadolinium kinetics, difﬁculty nulling the
myocardium, and a global subendocardialpattern of late gadolinium enhancement (LGE) (8).
However, the precise pattern of LGE has been re-
ported to bemore variable in recent studies (9,10). Our
impression has been that LGE is often diffuse
inATTRamyloidosis (4), but very fewATTRpatients
have been included in CMR studies, and there are no
reports of differences in LGE patterns according to
amyloid ﬁbril protein type. We report here the stan-
dard CMR measurements and LGE patterns in the
largest cohort of cardiac ATTR amyloidosis patients
characterized by using CMR at the time of writing.METHODS
Patients were identiﬁed between January 2007 and
June 2012 at the UK National Amyloidosis Centre,amyloidosis. All patients had a CMR scan for the
investigation of suspected amyloidosis. Histological
examination was performed in all cases, with immu-
nohistochemistry, to conﬁrm or rule out systemic
amyloidosis. Cardiac amyloidosis was conﬁrmed ac-
cording to results of endomyocardial biopsy, with
Congo red staining and immunohistochemistry to
determine the amyloid type. In the absence of cardiac
histology analysis, patients were diagnosed with car-
diac amyloidosis if there were extracardiac biopsy
results conﬁrming systemic amyloidosis, immuno-
histochemistry to determine the amyloid ﬁbril type
and echocardiographic criteria for cardiac amyloid-
osis (11). Transthyretin gene sequencing to differ-
entiate wild-type and mutant TTR was performed in
all cases of ATTR amyloidosis.
We obtained the raw CMR DICOM data for all
patients. De novo analysis was performed with
dedicated software (CMRtools 2012, Cardiovascu-
lar Imaging Solutions, London, United Kingdom)
and reported according to international guidelines
(12). Left ventricular (LV) volumes and mass were
indexed to body surface area. Patterns of LGE were
described in the left ventricle at 3 levels (base, mid-
ventricle, and apex) and in the right ventricular
(RV) free wall and atrium (present or absent). The
LGE pattern was described as transmural if it
involved the subendocardium through to the
epicardial layer.
Subendocardial LGE was described if there was
global subendocardial involvement but no trans-
mural LGE. Nulling was deﬁned as dark, unen-
hanced areas within the myocardium or skeletal
muscle in LGE images. The presence of pericardial
and pleural effusion was also recorded.
The study was approved by the ethics committee
of the Royal Free Hospital, and patients provided
informed written consent.
Statistics. Statistical analysis was performed using
SPSS version 17.0 (IBM SPSS Statistics, IBM
Corporation, Armonk, New York) or later statistical
packages. Parametric data are presented as mean  1
SD. Nonparametric data are presented as median
and interquartile range, and categorical data are
presented as frequencies and percentages. Com-
parison of categorical data was performed using
the chi-square test. Continuous variables were
compared using the unpaired Student t test for
parametric data and the Wilcoxon signed rank test
and Mann-Whitney test for nonparametric data.
Nonparametric correlations were performed by
using Spearman’s rank coefﬁcient. Survival analysis
was performed to September 2012 with mortality
Table 1. Baseline Differences Between Cardiac AL and ATTR
Amyloidosis Patients
Cardiac AL
Amyloidosis
(n [ 46)
Cardiac ATTR
Amyloidosis
(n [ 51) p Value
Age, yrs 63  9 74  7 <0.001
Male 27 (59) 45 (88) 0.009
Hypertension 6 (13) 10 (20) 0.38
NYHA functional class
I 10 (22) 7 (14)
II 23 (50) 28 (55) 0.59
III 13 (28) 15 (29)
IV 0 (0) 1 (2)
NT-proBNP, pMol/l 593 (172–1106) 497 (279–777) 0.48
Symptom duration before
diagnosis, months
11 (8–23) 11 (6–24) 0.70
Median survival, months 18 45 0.007
Values are mean  SD, n (%), or median (interquartile range).
AL ¼ light chain amyloid; ATTR ¼ transthyretin-related amyloidosis; NT-proBNP ¼
N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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135data linked to the UK Ofﬁce of National Statistics.
Survival is presented as Kaplan-Meier curves, with
the log-rank test used to compare groups. Multi-
variate regression analyses were made with all in-
dependent categorical and continuous variables that
appeared signiﬁcant (p < 0.05) and using backward
stepwise (likelihood ratio) logistic regression anal-
ysis. Intraclass correlation was used to evaluate
interobserver measurement reliability, expressed as a
single measure calculation.
RESULTS
A total of 115 CMR studies were obtained. We
performed complete analysis of 108 studies; 7 scans
with insufﬁcient data were not included in the
analyses. Studies were received from 46 different
centers. Only 1 center (St. George’s Hospital in
South London) performed >10 of the studies
analyzed in this series (24 [22%]). Most studies
(84%) were performed at 1.5-T ﬁeld strength; 17
studies (16%) were performed at 3.0-T ﬁeld strength.
A ﬁnal diagnosis of cardiac amyloidosis was
made in 100 patients (93%). The cardiac amyloid-
osis type was AL in 46 patients (46% [83% lambda
and 17% kappa type]) and ATTR in 51 patients
(51%, including 28 patients with senile systemic
amyloidosis secondary to wild-type nonmutant
ATTR and 23 patients with hereditary amyloidosis
secondary to mutant TTR). Non-AL, non-TTR
cardiac amyloidosis was diagnosed in 3 patients (3%;
AA amyloidosis (causative protein serum amyloid A
[SAA]) in 2 patients and apolipoprotein A1 in 1
patient). Cardiac histology results were available in
50 patients overall (46.3%), but the remaining pa-
tients all had extracardiac biopsy conﬁrmation of
systemic amyloidosis, and cardiac involvement was
deﬁned according to international guidelines (11).
Cardiac amyloidosis was ruled out on the basis
of endomyocardial biopsy results in 6 patients after
a CMR report with amyloid in the differential
diagnosis. The ﬁnal diagnosis in patients without
cardiac amyloidosis was as follows: hypertensive
cardiomyopathy in 3 patients, hypertrophic car-
diomyopathy in 2 patients, and alcoholic cardio-
myopathy in 1 patient. Results of CMR were
normal in 2 patients with systemic AL amyloidosis
in whom cardiac involvement was ruled out accor-
ding to conventional echocardiographic criteria.
(See Online Fig. 1 for a ﬂowchart of patients
included in the study.)
Differentiating cardiac ATTR from cardiac AL
amyloidosis. We focused on the differences be-
tween cardiac AL and ATTR amyloidosis, the mostcommon causes of cardiac involvement in systemic
amyloidosis.
BASELINE CHARACTERISTICS. Baseline differences
between AL and ATTR amyloidosis are presented
in Table 1. Patients with cardiac ATTR amyloidosis
were older (74 vs. 63 years; p < 0.001) com-
pared with cardiac AL amyloidosis patients and
predominantly male (88% vs. 59%; p ¼ 0.009).
There was no signiﬁcant difference in New York
Heart Association functional class at presentation
or N-terminal pro–B-type natriuretic peptide
(NT-proBNP) concentration according to amyloid
ﬁbril type in this cohort.
SURVIVAL. Median survival from the date of diag-
nosis in patients with cardiac ATTR amyloidosis
was better (45 months) compared with cardiac AL
amyloidosis (18 months) (p ¼ 0.007) (Fig. 1).
CMR: CARDIAC DIMENSIONS AND FUNCTION. LV
volumes and left ventricular ejection fraction
(LVEF) were within the normal range, when
indexed for body surface area, in cardiac AL and
ATTR amyloidosis (Table 2). LV end-diastolic
and end-systolic volumes were signiﬁcantly lower
in AL compared with ATTR amyloidosis, but LV
stroke volume was similar in both amyloid types
(71  19 ml vs. 72  20 ml; p ¼ 0.997). Thus,
LVEF was signiﬁcantly lower in cardiac ATTR
compared with AL amyloidosis (56% vs. 64%; p ¼
0.002), albeit with absolute and indexed values
within the normal range for both amyloidosis
Figure 1. Survival in Amyloidosis
Kaplan-Meier survival curves for cardiac light chain amyloid (AL) and
transthyretin-related (ATTR) amyloidosis (median survival 18 months and
45 months, respectively, from the date of diagnosis [p ¼ 0.007]).
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136subtypes. LV mass index was only mildly increased
in cardiac AL amyloidosis but was markedly
increased in cardiac ATTR compared with AL
amyloidosis. Interventricular septum and RV free
wall thickness were increased in both amyloidosis
types, with signiﬁcantly increased wall thickness
in cardiac ATTR (left ventricle 18  2 mm; right
ventricle 8  2 mm) compared with cardiac AL
amyloidosis (left ventricle 14  3 mm; right
ventricle 6  2 mm) (p < 0.001). Pleural effusions
were common despite preserved LVEF (observed in
57% of cardiac AL patients and 41% of ATTR
amyloidosis patients [p ¼ 0.13]). There was no
signiﬁcant difference in the prevalence of pericardial
effusions according to amyloid type (AL 37%;
ATTR 33% [p ¼ 0.71]).
CMR: LGE. LGE was present in all patients
with cardiac ATTR amyloidosis and 45 (98%) of 46
patients with cardiac AL amyloidosis (Table 3). One
male patient with cardiac AL amyloidosis according
to conventional echocardiographic criteria did not
demonstrate any LGE in the context of increased
LV thickness (13 mm), increased LV mass index
(93 g/m2), and preserved systolic function (LVEF
75%). RV free wall LGE was detectable in all
patients with ATTR amyloidosis but in only 33
patients (72%) with cardiac AL amyloidosis
(p < 0.001), possibly due to a lesser degree of RV
thickening in AL amyloidosis. RV wall thickness
was signiﬁcantly higher in patients with detectable
RV LGE (7  2 mm) compared with patients
without RV LGE (5  2 mm) (p < 0.001). AtrialLGE was detectable in 47 ATTR patients (92%)
and 34 cardiac AL amyloidosis patients (74%)
(p ¼ 0.02). The previously reported global sub-
endocardial pattern of LGE (8) was present in
18 AL patients (39%) and only 6 ATTR patients
(12%) (p¼ 0.002). The prevalence of any transmural
LGE was signiﬁcantly higher in patients with car-
diac ATTR amyloidosis (n¼ 46 [90%]) than cardiac
AL amyloidosis (n¼ 17 [37%]) (p< 0.001). A base-
apex gradient (more extensive uptake at the base
compared with the apex) (Fig. 2) was present in 36
cardiac ATTR patients (71%) and 19 cardiac AL
patients (41%) (p ¼ 0.004). Global transmural LGE
throughout the left ventricle was evident in 11
ATTR patients (22%) but in only 2 patients with
cardiac AL amyloidosis (4%) (p ¼ 0.01).
Quantiﬁcation of LGE in cardiac amyloidosis. The
extent of LGE in ATTR amyloidosis was strikingly
greater than that observed in AL amyloidosis.
We devised a new retrospective analysis tool to
semi-quantitatively assess the degree of LGE in
patients with suspected cardiac amyloidosis (Fig. 3).
The Query Amyloid Late Enhancement (QALE)
score was performed on LGE images at the base,
mid-ventricle, and apex. The maximum LV LGE
score at each level is 4 (maximum LV LGE score
12), plus 6 if RV LGE is present. The QALE score
range is 0 (no LGE in the left or right ventricle)
to 18 (global transmural LV LGE with RV
involvement).
A signiﬁcant, positive correlation was demon-
strated between QALE score and interventri-
cular septal thickness (Spearman’s rho ¼ 0.344,
p < 0.001), LV mass index (Spearman’s rho ¼
0.348, p < 0.001), LV end-diastolic volume index
(Spearman’s rho = 0.206, p ¼ 0.033), and LV
end-systolic volume index (Spearman’s rho ¼ 0.269,
p ¼ 0.005). A negative correlation was demon-
strated between QALE score and LVEF (Spear-
man’s rho ¼ –0.267, p ¼ 0.005). No signiﬁcant
correlation was observed between QALE score and
LV stroke volume index (Spearman’s rho ¼ 0.011,
p ¼ 0.910), NT-proBNP (Spearman’s rho ¼ 0.068,
p ¼ 0.487), or duration of symptoms (Spearman’s
rho ¼ –0.054, p ¼ 0.579).
Multivariate regression analysis was performed
by using clinical and CMR variables (age, sex,
interventricular septum thickness, LV mass, and
QALE score). The QALE score was identiﬁed
as an independent predictor of amyloid type
(odds ratio: 1.9 [95% conﬁdence interval (CI): 1.2
to 3.0]; p ¼ 0.007) (Online Table 1). A score
model for the detection of ATTR amyloidosis was
Table 2. Comparison of AL and ATTR Amyloidosis (CMR)
AL Amyloidosis
(n [ 46)
ATTR
(n [ 51) p Value
LVEDV, ml 114  31 131  39 0.023
Men (normalized
range 60–95 ml)
64  16 69  20 0.258
Women (normalized
range 53–87 ml/m2)
60  16 62  11 0.789
LVESV, ml 43  20 59  28 0.001
Men* (normalized
range 14–36 ml/m2)
24  10 32  15 0.011
Womeny (normalized
range 13–31 ml/m2)
22  13 25  12 0.632
LV SV, ml 71  19 72  20 0.997
Men* (normalized
range 40–64 ml/m2)
41  11 38  10 0.256
Womeny (normalized
range 36–60 ml/m2)
37  9 37  4 0.944
LVEF, % 64  12 56  12 0.002
Men* (range 55%–81%) 63  11 55  12 0.008
Womeny (range 57%–81%) 66  13 62  14 0.538
LV mass, g 167 (137–191) 228 (202–267) <0.001
Men* (normalized
range 57–90 g/m2)
93 (82–106) 122 (106–140) <0.001
Womeny (normalized
range 48–78 g/m2)
83 (67–102) 104 (95–116) 0.050
Interventricular septum
thickness, mm
14  3 18  2 <0.001
RV free wall thickness, mm 6  2 8  2 <0.001
Left atrium area, cm2 23  7 26  7 0.04
Right atrium area, cm2 20  7 25  8 0.001
Pericardial effusion 17 (37) 17 (33) 0.71
Pleural effusion 26 (57) 21 (41) 0.13
Values were indexed for body surface area and are mean  SD, median (interquartile range),
or n (%). *AL ¼ 28 male patients; ATTR ¼ 45 male patients. yAL ¼ 19 female patients;
ATTR ¼ 6 female patients.
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricular; LVEDV ¼ left ventricular end-
diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular
end-systolic volume; RV ¼ right ventricular; SV ¼ stroke volume; other abbreviations as in
Table 1.
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137developed as a logistic probability unit (z ¼ logit
[p] ¼ log e (p/1-p); p ¼ 1/1þe-z) by using the
most signiﬁcant variables: age and interventricular
septum thickness with or without QALE score. A
receiver-operating characteristic curve was devel-
oped for the scores (Fig. 4). A QALE score $13
differentiated ATTR from AL type with 82%
sensitivity and 76% speciﬁcity. The logistic score
with QALE included was the most accurate, with
87% sensitivity and 96% speciﬁcity to detect
ATTR amyloidosis.
REPRODUCIBILITY OF QALE SCORE. All CMR
scans were reported by a second blinded observer to
determine the interoperator variability of QALE
scoring. The second observer reviewed the entire
study and recorded the QALE score in the left
ventricle (3 levels) and the right ventricle. The
intraclass correlation coefﬁcient was 0.66 (95% CI:
0.53 to 0.76), conﬁrming fair agreement between
the 2 independent observers. Bland-Altman analysis
(13) demonstrated a mean difference of –1.28 (95%
CI: for mean difference –0.48 to –2.09) (Fig. 5).
Comparison with CMR reports: all patients. TRUE
POSITIVE AND TRUE NEGATIVE CMR REPORTS. The
referring hospital CMR report correctly identiﬁed
cardiac amyloidosis in 88 patients and correctly
ruled out cardiac amyloidosis in 2 patients with
systemic AL amyloidosis who had no evidence
of cardiac involvement according to conventional
echocardiographic criteria.
FALSE-POSITIVE CMR REPORTS. Cardiac amyloid-
osis was ruled out on the basis of endomyocar-
dial biopsy results in 6 patients after CMR
reported ﬁndings suggestive of amyloid cardiomy-
opathy. The false-positive cases are summarized in
Online Table 2. All 6 patients were male, with
Afro-Caribbean ethnicity in 4 cases, and all showed
LGE on CMR imaging, but extensive myocardial
ﬁbrosis was demonstrated according to histology in
each case with negative Congo red staining. The
pattern of LGE was variable, but diffuse mid-wall
LGE was seen in 2 hypertensive Afro-Caribbean
patients (Fig. 6). None of the patients with false-
positive reports demonstrated transmural LGE or a
base-apex gradient.
FALSE-NEGATIVE CMR REPORTS. Cardiac amyloid-
osis had not been included in the differential diag-
nosis for 12 patients in whom cardiac amyloidosis
was later conﬁrmed using conventional echocardio-
graphic criteria, including 11 patients with AL
type and 1 patient with ATTR type. The conclusions
of the reports were as follows: “not suggestive ofcardiac amyloidosis” in 5 patients; “inconclusive”
in 2 patients; “consistent with hypertrophic
cardiomyopathy” in 2 patients; “consistent with
myocardial infarction” in 2 patients; and “possible
Fabry’s disease” in 1 patient. LGE was evident in all
cases. Only 1 patient demonstrated the previously
reported global subendocardial LGE pattern (8).
The other patterns of LV LGE in false-negative
CMR scans were transmural in $1 segment in 6
patients (50%), patchy (n ¼ 4), or mid-wall with
apical sparing (n ¼ 1). RV LGE was evident in 8
patients (67%), and a base-apex gradient was
evident in 5 patients (42%). Pleural effusions were
evident in 6 patients (50%) despite normal LVEF
and volumes.
Figure 2.
(Left) A h
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horizonta
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Table 3. Comparison of AL and ATTR Amyloidosis (LGE)
Cardiac AL
Amyloidosis
(n [ 46)
Cardiac ATTR
(n [ 51) p Value
LV LGE 45 (98) 51 (100) 0.47
RV LGE 33 (72) 51 (100) <0.001
Global subendocardial LGE 18 (39) 6 (12) 0.002
Global transmural LGE 2 (4) 11 (22) 0.01
Any transmural LGE 17 (37) 46 (90) <0.001
Base-apex gradient 19 (41) 36 (71) 0.004
Atrial LGE 34 (74) 47 (92) 0.02
Suboptimal myocardial nulling 8 (17) 17 (33) 0.07
Values are n (%).
LV ¼ left ventricular; LGE ¼ late gadolinium enhancement; RV ¼ right ventricular; other
abbreviations as in Table 1.
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138Non-AL, non-ATTR cardiac amyloidosis. CMR in 2
patients with cardiac AA amyloidosis (1 male age
70 years, 1 female age 60 years) demonstrated
moderate LV thickening (16 and 15 mm, respec-
tively), normal/mildly increased LV mass index
(82 and 91 g/m2), low normal LV end-diastolic
volume index (58 and 61 ml/m2), very low LV
end-systolic volume index (both 10 ml/m2), and
high LVEF (82% and 84%). The pattern of LGE
was diffuse with transmural involvement and a
base-apex gradient in both cases, similar to that
seen in ATTR amyloidosis. A 50-year-old female
patient with cardiac apolipoprotein A1 (variant
L60R) amyloidosis demonstrated mildly increased
wall thickness (13 mm), normal LV mass, reduced
LV volumes, high LVEF (78%), and subendo-
cardial LGE with transmural involvement of theExamples of LGE Patterns in ATTR and AL Amyloidosis
orizontal long-axis late gadolinium enhancement (LGE) image from a
ith ATTR amyloidosis, highlighting the base-apex gradient. (Right) A
l long-axis image from a patient with cardiac AL amyloidosis with
endocardial LGE. Abbreviations as in Figure 1.lateral wall (more similar to the AL pattern of
LGE).
D I SCUSS ION
Cardiac amyloidosis of all types is associated with
LV volumes and LVEF within the normal range at
presentation, but LV wall thickness and mass index
are increased. In our experience, preserved LVEF by
echocardiography is uncommon as the disease pro-
gresses and it should be noted that the CMR scans
in this series were performed early, often before a
formal diagnosis had been made, and not repeated.
Cardiac ATTR amyloidosis is associated with
signiﬁcantly higher LV mass index, higher LV
volumes, and lower LVEF compared with cardiac
AL amyloidosis. Pleural and pericardial effusions
were more common in cardiac AL amyloidosis,
despite better LVEF and smaller LV volumes,
although not statistically signiﬁcant.
LGE was evident in all but 1 patient with cardiac
AL amyloidosis in this series. Two patients with
systemic AL amyloidosis and no evidence of cardiac
involvement according to conventional echocardio-
graphic criteria had completely normal CMR scans.
The pattern of LGE in cardiac ATTR amyloidosis
was more extensive, with RV enhancement detected
in all cases and a higher prevalence of transmural LV
LGE. The absence of detectable RV free wall LGE
in more than one-quarter of patients with cardiac
AL amyloidosis may distinguish the 2 subtypes;
however, the difference in detection of RV LGE
may be explained by increased RV wall thickness in
ATTR amyloidosis. Suboptimal myocardial nul-
ling was a frequent ﬁnding in this series and in itself
should raise suspicion of amyloid inﬁltration.
T1-weighted scouting sequences (Look-Locker)
incorporating a range of inversion times are helpful
to differentiate extensive LGE from poor myocardial
nulling. It may also be helpful to cross-check skeletal
muscle signal intensity while choosing the optimal
inversion time, particularly in difﬁcult cases; very
bright skeletal muscle signal should prompt a
reconsideration of the inversion time (Fig. 7).
Gadolinium is an extracellular tracer, and previ-
ous studies have conﬁrmed good correlation bet-
ween LGE and increased extracellular space on
histological examination in aortic stenosis (14)
and cardiac amyloidosis (8). A base-apex gradient,
common in ATTR amyloidosis in this study, cor-
relates with echocardiographic studies using strain
analysis, which have reported reduced basal systolic
longitudinal and radial strain (“apical sparing”) in
cardiac amyloidosis (15). The base-apical gradient
Figure 3. QALE Score Deﬁnition
The Query Amyloid Late Enhancement (QALE) score was performed on late gadolinium enhancement (LGE) images at the base, mid ventricle
and apex in the left ventricle (LV) and right ventricle (RV). Each LV level is scored according to the degree of LGE, with the highest score for
circumferential and transmural LV LGE. The maximum LV LGE score at each level is 4 (maximum total LV LGE score ¼ 12). The presence of any
detectable RV LGE scores þ6. The QALE score range for the whole heart in each patient is from 0 (no detectable LGE in the LV or RV) to 18
(global transmural LV LGE at all 3 levels plus RV involvement).
Figure 4. ROC Curves
(Red) QALE score, area under the curve (AUC) 0.82 (95% conﬁdence interval
[CI]: 0.74 to 0.91); sensitivity 82%; speciﬁcity 76%. (Blue) logistic regression
model (age and interventricular septum thickness) without QALE, AUC 0.92
(95% CI: 0.86 to 0.97); sensitivity 85%; speciﬁcity 88%. (Green) logistic
regression model with QALE, AUC 0.95 (95% CI: 0.90 to 1.00); sensitivity 87%;
speciﬁcity 96%. Abbreviation as in Figure 3.
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139also reﬂects underlying myocardial wall stress in
the left ventricle (16).
It remains unclear why survival in cardiac
AL amyloidosis is inferior to cardiac ATTR amy-
loidosis. LGE has been reported as a marker of poor
prognosis in ischemic, dilated, and hypertrophic
cardiomyopathies (17–19). Although Syed et al.
(10) reported increased B-natriuretic peptide con-
centration in amyloidosis patients (predominantly
AL type) with LGE, there was no correlation bet-
ween NT-proBNP and LGE when quantiﬁed with
the QALE score in this study. Patients with cardiac
ATTR amyloidosis in this series had a better
prognosis despite more extensive LGE. The previ-
ously reported subendocardial LGE pattern is
characteristic of AL amyloidosis, but it is very often
not global as described and incorporates a degree
of transmural enhancement, typically in the
basal lateral wall. We have therefore reﬁned the
description of global subendocardial LGE resulting
in the pattern presenting infrequently in this series.
It is possible that the precise anatomical pattern
of LGE (rather than merely the extent of LGE)
in amyloidosis has a major inﬂuence on causing
cardiac dysfunction, with subendocardial deposi-
tion potentially causing more marked restrictivephysiology. Diastolic function is not formally
assessed with routine CMR, and correlation of the
ﬁndings in this study with echocardiography is
warranted. Direct toxicity of AL amyloid ﬁbrils on
Figure 5. Reproducibility of QALE Scores
Bland-Altman plot demonstrating good agreement between 2 independent
observers reporting QALE scores in patients with AL and ATTR cardiac
amyloidosis (blue line ¼ mean difference; grey lines ¼ 2 SDs from the mean
difference; upper limit 6.53; lower limit –9.09). Abbreviations as in Figures 1 and 3.
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140myocardial cells has been proposed as an alternative
explanation (20), but it is also possible that the
likely much slower accumulation of ATTR amy-
loid is better tolerated. No signiﬁcant difference
was demonstrated between nonmutant (n ¼ 23)
and mutant ATTR (n ¼ 28) type for any CMR
variable in this series.
The newly devised CMR LGE scoring out-
lined in this study was an independent predictor of
amyloid type on multivariate analysis. The logisticFigure 6. False-Positive Example
An example of diffuse mid-wall LGE reported as suggestive of
cardiac amyloidosis. Cardiac biopsy results demonstrated exten-
sive myocardial ﬁbrosis with negative Congo red staining. This
pattern was found in 2 Afro-Caribbean patients with hypertensive
heart disease. Abbreviation as in Figure 2.regression scoring model differentiated ATTR
and AL type with high sensitivity and speciﬁcity,
and we have conﬁrmed an improvement in accuracy
by adding the QALE score. Echocardiography
has poor speciﬁcity (74% to 82%) to detect amy-
loid from nonamyloid cardiomyopathy (21), even
using modern speckle tracking strain analysis tech-
niques (15), and it thus seems inferior to CMR
in differentiating between amyloid types (although
this has not been formally assessed). 99mTc-3,3-
diphos- phono-1,2-propanodicarboxylic acid (DPD)
scintigraphy seems to have high speciﬁcity to differ-
entiate amyloid types, but it has been studied in
much smaller numbers (22). CMR is currently more
widely available than 99mTc-DPD scintigraphy and
also provides additional functional and structural
information.
CMR LGE scoring seems to differentiate bet-
ween amyloid types but the technique requires
validation in additional prospective studies. Novel
T1 mapping techniques have been shown to pro-
vide quantitative assessment of diffuse extracellular
expansion in other cardiomyopathies (23,24). T1
mapping may become the gold standard for quan-
tifying the extent of interstitial expansion by amy-
loid deposition (25), but it may not be possible to
implement the technique into standard clinical
practice for all patients due to limited availability
(CMR scanning is often performed locally before
specialist center referral).
Given the retrospective nature of the current
study, and the lack of evaluation in a prospective
cohort, we accept that treatment decisions should
not be based on CMR ﬁndings alone, and histo-
logical diagnosis (including amyloid type differen-
tiation) remains the gold standard. LGE is not
speciﬁc to cardiac amyloidosis, and false-positive
reporting occurs in the clinical setting. Extensive
ﬁbrosis, for example secondary to hypertrophic
cardiomyopathy or hypertensive heart disease, may
result in diffuse LGE and false-positive CMR
ﬁndings. The absence of transmural LGE or a
base-apex gradient in all patients with false-positive
CMR reports in this series may help to identify
patients requiring further noninvasive investigation
(e.g., 99mTc-DPD scintigraphy) before proceeding
to endomyocardial biopsy.
Study limitations. We reported a retrospective anal-
ysis of CMR studies. De novo analyses were per-
formed by using the original DICOM data;
however, we accept the inherent bias of retrospec-
tive, nonrandomized studies. Multiple CMR scan-
ners and protocols were used in this series, and we
acknowledge a signiﬁcant referral bias because we
Figure 7. Using the Skeletal Muscle Signal to Guide the Choice of
Inversion Time for Myocardial LGE Analysis
(Left panel) Myocardium (dotted arrow) appears to null before the blood
pool (TI, 275 ms), suggesting cardiac amyloidosis. Note increased skeletal
muscle signal intensity (solid arrow). (Right panel) Blood pool is nulled at a
longer inversion time (TI, 341 ms). Myocardium (dotted arrow) demonstrates
diffuse late gadolinium enhancement (LGE), and skeletal muscle (solid arrow)
signal is not bright, suggesting a better inversion time for myocardial analysis.
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141did not include patients in whom amyloidosis was
not considered. Although a single-center, optimized
“amyloid protocol” is the ideal, in reality, patients
are referred to specialist centers from many different
units, and the diagnosis is not always known at the
time of the scan. Optimized LGE sequences for
utilization in ischemic cardiomyopathy are recog-
nized to provide reliable and reproducible ﬁndings
across vendors and ﬁeld strengths. Each study in
this series was reported separately by 2 CMR
operators, with 1 observer blinded to the ﬁnal
diagnosis, and the QALE score was compared for
all studies with fair reproducibility.
Scan quality is often suboptimal in cardiac
amyloidosis patients due to poor breath-holding,
arrhythmias, and effusions, and a total of 7 scans
obtained were uninterpretable and not included
in the analyses. Inability to adequately null the
myocardium was evident in 25% of cases with AL or
ATTR type, but, with persistent effort, sufﬁcient
information was derived in the majority. The con-
clusions on the original reports were generally sound,
but paradoxical deductions were reached in a few
cases (e.g., no LGE reported despite phase-sensitive
inversion recovery sequences demonstrating diffuse
transmural enhancement, which was disregarded due
to suboptimal nulling).
We used gold standard echocardiographic criteria
in AL amyloidosis for comparison of CMR data
because endomyocardial biopsy testing is not always
appropriate, particularly in patients with noncardiac
biopsy proof of amyloidosis type. Conventional
noninvasive criteria for cardiac ATTR amyloidosis
were not available at the time of publication.
CONCLUS IONS
CMR is often performed to assess patients with
suspected amyloidosis or it triggers the differential
after an abnormal scan result. The increased avail-
ability of CMR will ultimately lead to increased
detection of cardiac amyloidosis due to superior
tissue characterization, using the LGE technique,
compared with echocardiography. This study was
a real-world analysis of scans performed in 46 centers
without specialist amyloid protocols, and we
acknowledge all of the difﬁculties of the LGE tech-
nique. Despite these limitations, the analysis was
robust in identifying the amyloid ﬁbril type with high
accuracy. CMR LGE scoring has the potential to
enhance the management of many patients but
cannot replace biopsy as the gold standard.
Cardiac amyloidosis should be considered in
any patient with LGE and LV hypertrophy,particularly in the presence of preserved ejection
fraction and pleural effusions. We have attempted
to differentiate between the 2 main subtypes of
cardiac amyloidosis, a crucial differentiation due
to markedly different outcomes. Cardiac ATTR
amyloidosis is associated with improved survival
despite increased LV mass and more extensive
LGE, a ﬁnding at odds with other cardiomyopa-
thies. The explanation for this ﬁnding needs further
investigation.
Correct identiﬁcation of amyloidosis type is
imperative to differentiate patients with cardiac AL
amyloidosis, a condition potentially amenable to
chemotherapy, from cardiac ATTR amyloidosis
patients who may beneﬁt from novel TTR-speciﬁc
treatments now entering Phase III clinical trial
assessment.
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